A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII)

Table 1 Randomized controlled trials in elderly patients with glioblastoma

Authors, publication year, study name	Age cut-off, years	Number	Intervention	mPFS, months	mOS, months
Roa et al., 2004 [11]	≥60	47	60 Gy/30 fr	N/A	5.1
		48	40 Gy/15 fr	N/A	5.6
Keime-Guibert et al., 2007 [14], ANOCEF	≥70	42	Best supportive care	1.2	3.9
		39	50 Gy/28 fr	3.4	6.7
Wick et al., 2012 [15], NOA-08	> 65	178	60 Gy/30 fr	4.7	9.6
		195	Dose-dense temozolomide	3.3	8.6
Malmström et al., 2012 [12], Nordic study	> 70	100	60 Gy/30 fr	N/A	6
		98	34 Gy/10 fr	N/A	7.5
		93	Temozolomide	N/A	8.3
Roa et al., 2015 [13]	≥65	50	40 Gy/15 fr	4.2	6.4
		48	25 Gy/5 fr	4.2	7.9
Perry et al., 2017 [10], CE.6	≥65	281	40 Gy/15 fr	3.9	7.6
		281	40 Gy/15 fr + temozolomide	5.3	9.3

mPFS median progression-free survival; mOS median overall survival; fr fractions; N/A not available

ISSN: 1471-2407